GlassScriptPhysician profile
Adrianne Dewalt Vaughn
NPI 1649263740
$6,712.87
in general payments reported to CMS, 2019-2025
21 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,153 · 2020: $116 · 2021: $125 · 2022: $1,167 · 2023: $1,387 · 2024: $1,253 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,152.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,749.27 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,578.86 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $479.24 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $377.25 | 2019-2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $342.52 | 2024-2025 | |
| Shire North American Group INC | $247.07 | 2019 | |
| Genentech USA, INC. | $237.40 | 2019-2024 | Xolair |
| Grifols USA, LLC | $204.15 | 2024-2025 | Xembify |
| Alk-Abello, INC | $161.82 | 2019-2025 | Odactra, Ragwitek, Grastek |
| Genentech, INC. | $155.00 | 2024 | Xolair |
| Sunovion Pharmaceuticals INC. | $141.49 | 2019 | |
| Blueprint Medicines Corporation | $132.08 | 2022-2023 | |
| Incyte Corporation | $125.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $112.13 | 2025 | Neffy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $100.43 | 2023 | Auvi-Q |
| Pfizer INC. | $98.78 | 2022 | |
| Amgen INC. | $97.02 | 2022 | |
| Csl Behring | $91.10 | 2019 | |
| Adma Biomanufacturing LLC | $90.76 | 2025 | |
| Sanofi-Aventis U.S. LLC | $66.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrianne Vaughn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.